Therapeutic options here are based on EMA drug approvals with deviating approval details clearly marked. Drugs availability may vary in your country.

What services are provided by the FGFR-Portal?

Quality in Pathology GmbH (QuIP) was established with the aim of providing support services to pathologists in Germany and Europe, optimizing their testing results, and offering assistance for all of the relevant scientific and organizational activities required for quality assurance work. The FGFR-Portal was set up to offer pathologists, consultants working in other disciplines, and oncologists orientation at the interface between biomarker tests and therapy options. The Portal hosts a biomarker-based therapy algorithm. This algorithm is based both on current medical guideline recommendations as well as the latest scientific findings, and provides full details of the underlying investigations.


FGFR pathway alterations have been implicated in approximately 7 % of cancer entities. Due to the proliferative behavior of FGFR alterations in cancer, FGFR inhibitors have emerged as potential targeted therapeutic agents in recent years. The promising results of FGFR inhibitors in advanced unresectable cholangiocarcinoma harboring FGFR2 fusions and in metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic alterations led to their accelerated approval in cholangiocarcinoma and urothelial carcinoma.

While specific biomarker-tested therapies for advanced altered urothelial and cholangiocarcinoma have been approved, additional studies are being conducted on various tumor entities which could expand the use of this specific inhibitor for different types of cancers. The portal will provide comprehensive information on different FGFR alterations and their detection, serving as an interdisciplinary resource for diagnostics, molecular pathology and biomarker determination for a wide range of tumor entities. It includes algorithms that offer detailed information on tests, corresponding results and different therapy options. In parallel, users will be able to access the portal via specific tumor entities or via approved drugs.The content of the FGFR portal is developed in collaboration with and reviewed by recognized experts in the field.

References and citations on the Portal

The underlying sources from the research literature consulted by the portal content authors are cited as a list on a separate “References” tab on each of the relevant algorithm pages. In each case, these research references and citations reflect the current state of progress on the part of the scientific experts, and will be updated/amended regularly by the team as necessary.


Please note: While we have taken the greatest of care in preparing the information provided on our FGFR-Portal, we cannot accept any liability for the completeness, accuracy, and/or how current the information provided is. This applies in particular to third-party content made accessible on our website by the links to this content that we have provided. Please consult the summary of product characteristics for each drug compound to obtain current and/or further information.

Please also note that the material discussed here is generally characterized by the fact that pathologists may not necessarily agree on the specific details of an interpretation of the same set of images. We therefore always state the underlying data set on which the evaluation of the section is based in the reference sections. You bear sole responsibility for the evaluation of your own slides. Please contact us if you have any questions.

Quality in Pathology GmbH

The FGFR portal is supported by IncyteJanssen-Cilag and Taiho Oncology Europe